Journal of Molecular Signaling · 2011 · 145 citations · 40 references
MedicineOncologyPharmacologyCarcinogenesisChemotherapyMolecular OncologyCancer Stem Cell BiologyCancer Stem CellsChemotherapy ResistanceColorectal CancerMalignant NeoplasmsStem Cell TumorigenicityCancer Stem Cell - Mediated ResistanceCancer Stem Cell MarkersCancer Stem Cell TargetingCancer Stem Cell-mediated ResistanceColorectal AdenomasCombination TherapyOxaliplatin-based TherapyTherapy-resistant Cancer Stem Cells
Metastatic colorectal cancer remains a serious health concern with poor patient survival. Although 5-Fluorouracil (5-FU) or 5-FU plus oxaliplatin (FOLFOX) is the standard therapy for colorectal cancer, it has met with limited success. Recurrence of the tumor after chemotherapy could partly be explained by the enrichment of the chemo-resistant sub-population of cancer stem cells (CSCs) that possess the ability for self-renewal and differentiation into different lineages in the tumor. Therefore development of therapeutic strategies that target CSCs for successful treatment of this malignancy is warranted. The current investigation was undertaken to examine the effectiveness of the combination therapy of dasatinib (a Src inhibitor) and curcumin (a dietary agent with pleiotropic effect) in inhibiting the growth and other properties of carcinogenesis of chemo-resistant colon cancer cells that are enriched in CSCs sub-population. Remnants of spontaneous adenomas from APCMin +/- mice treated with dasatinib and/or curcumin were analyzed for several cancer stem cell markers (ALDH, CD44, CD133 and CD166). Human colon cancer cells HCT-116 (p53 wild type; K-ras mutant) and HT-29 (p53 mutant; K-ras wild type) were used to generate FOLFOX resistant (referred to as CR) cells. The effectiveness of the combination therapy in inhibiting growth, invasive potential and stemness was examined in colon cancer CR cells. The residual tumors from APCMin +/- mice treated with dasatinib and/or curcumin showed 80-90% decrease in the expression of the CSC markers ALDH, CD44, CD133, CD166. The colon cancer CR cells showed a higher expression of CSCs markers, cell invasion potential and ability to form colonospheres, compared to the corresponding parental cells. The combination therapy of dasatinib and curcumin demonstrated synergistic interactions in CR HCT-116 and CR HT-29 cells, as determined by Calcusyn analysis. The combinatorial therapy inhibited cellular growth, invasion and colonosphere formation and also reduced CSC population as evidenced by the decreased expression of CSC specific markers: CD133, CD44, CD166 and ALDH. Our data suggest that the combination therapy of dasatinib and curcumin may be a therapeutic strategy for re-emergence of chemo-resistant colon cancer by targeting CSC sub-population.
40
Prospective identification of tumorigenic breast cancer cells
Muhammad Al‐Hajj, Max S. Wicha, Adalberto Benito‐Hernández et al. · Proceedings of the National Academy of Sciences · 2003 · 10.4K citations · Full text
Medicine, Cell Biology, Oncology +11
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
Catherine O′Brien, Aaron Pollett, Steven Gallinger et al. · Nature · 2006 · 4.1K citations
Medicine, Cancer Biology, Oncology +11
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André, C. Boni, Lamia Mounedji-Boudiaf et al. · New England Journal of Medicine · 2004 · 3.7K citations · Full text
CD44 is the principal cell surface receptor for hyaluronate
Alejandro Aruffo, Ivan Stamenkovic, Michael Melnick et al. · Cell · 1990 · 2.5K citations